To explore the relevance of lncRNA to EGFR‐TKI in patients with EGFR mutation‐positive NSCLC, we performed a Kaplan‐Meier analysis of PFS in 59 patients and found that patients with high plasma MALAT1 (≥median) expression after treatment with EGFR‐TKI had longer PFS indicating that plasma MALAT1 has the potential to predict the efficacy of EGFR mutation‐positive EGFR‐TKI. The gene discussed is MALAT1; the disease is non-small cell lung carcinoma.